Simple Summary This review article addresses the toxic effects on the heart associated with
the use of certain cancer-treating drugs known as immune checkpoint inhibitors. These …

Over the last decade or so, there has been a paradigm shift in the oncologic care of patients
with a range of solid tumour and haematologic malignancies, away from traditional cytotoxic …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

As the clinical applications of immune checkpoint inhibitors (ICIs) expand, our knowledge of
the potential adverse effects of these drugs continues to broaden. Emerging evidence …

Abstract Purpose of Review Immune checkpoint inhibitors (ICIs) have improved the field of
cancer, especially in patients with advanced malignancies. Nevertheless, cardiovascular …

Objectives Immune checkpoint inhibitors are associated with adverse cardiovascular events.
However, there are no data characterizing cardiovascular events among Asians on immune …

The broad application of immune checkpoint inhibitors (ICIs) has led to significant gains in
cancer outcomes. By abrogating inhibitory signals, ICIs promote T cell targeting of cancer …

Abstract Purpose of Review Patients with lung cancer often have concomitant
cardiovascular comorbidities and receive potentially cardiotoxic therapies. As oncologic …

The development of immune checkpoint inhibitors (ICIs) has provided a novel and
revolutionary treatment option for previously incurable cancers. However, this major …

Immune checkpoint inhibitors (ICIs) are monoclonal antibody antagonists, which can block
cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed death-1/ligand-1 (PD-1/PD-L1) …